Biome Analytics Supports Research Aimed at Saving Lives and Improving Outcomes in Cardiovascular Procedure

Research featured in JAHA article: Refining Safe Contrast Limits for Preventing Acute Kidney Injury After Percutaneous Coronary Intervention

SAN FRANCISCO–(BUSINESS WIRE)–Biome Analytics, the leading cardiovascular performance company, announces the results of original research published in the Journal of the American Heart Association (JAHA).

Cardiovascular disease remains the leading cause of morbidity and mortality in the United States, with coronary artery disease being the most common type of heart disease. Percutaneous coronary intervention (PCI) is the treatment of choice for refractory symptomatic coronary artery disease and acute coronary syndromes, with more than 660,000 PCIs performed annually across the country. Up to 14% of all PCIs are complicated by postprocedure acute kidney injury, also known as contrast-associated acute kidney injury (CA-AKI). Patients who develop CA-AKI suffer not only from longer and more costly hospital stays but also from increased mortality, including a 36% chance of death during hospitalization and a 12% chance of dying within 1 year of hospital discharge.

Authored by Neal Yuan, MD, and coauthored by Patrick G. Botting MSPH, Yaron Elad MD, Steven M. Bradley MD, Teryl K. Nuckols, MD, Susan Cheng, MD MPH, Joseph E. Ebinger MD MPH, and Khalid Latif, PhD, Biome’s vice president of research and development, Refining Safe Contrast Limits for Preventing Acute Kidney Injury After Percutaneous Coronary Intervention explores root causes for morbidity associated with CA-AKI, and asserts that this morbidity may be prevented by using less contrast during PCI. Unfortunately, the tools for determining safe contrast volumes are limited, leading the research team to develop, test, and prove risk models that clinicians can use at the point of care, which require no need for additional data inputs, and at the same time is tailored to achieving safe contrast volume limits during PCI.

The research concluded that compared with preexisting equations, new multivariate models for safe contrast limits were substantially more accurate in predicting CA-AKI and could help determine which patients benefit most from limiting contrast during PCI. These models are immediately available to subscribers of Biome performance applications.

To review the article visit:

For more information about Biome Analytics, or to schedule a demo, visit

About Biome Analytics

Biome ( is the leading cardiovascular performance company dedicated to helping doctors and health systems deliver the best care, to the most patients, at the lowest cost. Biome partners with ambitious enterprise heart centers and cardiovascular teams looking to achieve superior clinical and financial performance. Clients rely on Biome’s proprietary machine learning, human-enabled technology, and Biome’s community-driven Knowledge Network™ to activate their data assets, engage physicians, and accelerate performance improvement. Within days of onboarding, clients gain actionable insights with minimal impact on IT resources. Based in San Francisco, with offices in Chicago and New York, the UCSF Digital Health awards recognized Biome as a “Top 10 Best Patient Cost Savings” solution.

Works Cited:

Journal of the American Heart Association. “Refining Safe Contrast Limits for Preventing Acute Kidney Injury After Percutaneous Coronary Intervention.” Journal of the American Heart Association, Volume 10, Issue 15 January 2021. Accessed 17 December 2020.


Stuart Jacobson

CEO & Chairman